Clinical trial
Safety and Efficacy of MCC-257 in the Treatment of Diabetic Polyneuropathy
NCT00307749 · Tanabe Pharma Corporation, Industry · Completed
Key facts
| NCT number | NCT00307749 |
|---|---|
| Title | Safety and Efficacy of MCC-257 in the Treatment of Diabetic Polyneuropathy |
| Official title | A Phase II, Randomized, Double-Blind, Placebo-Controlled, 24-Week Dose Finding Study to Evaluate the Efficacy and Safety of 20mg, 40mg and 80mg of MCC-257 in Patients With Mild to Moderate Diabetic Polyneuropathy |
| Lead sponsor | Tanabe Pharma Corporation, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Diabetic Polyneuropathy |
| Intervention type | Drug |
| Interventions | Placebo, MCC-257 |
| Enrollment | 420 |
| Start date | Mar 1, 2006 |
| Completion | Aug 1, 2007 |
| First posted | Mar 28, 2006 |
| Last update posted | Dec 28, 2007 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: